Objective. To determine if 1) patients have distinct affective reaction patterns to medication information, and 2) whether there is an association between affective reaction patterns and willingness to take medication. Methods. We measured affect in real time as subjects listened to a description of benefits and side effects for a hypothetical new medication. Subjects moved a dial on a handheld response system to indicate how they were feeling from ''Very Good'' to ''Very Bad''. Patterns of reactions were identified using a cluster-analytic statistical approach for multiple time series. Subjects subsequently rated their willingness to take the medication on a 7-point Likert scale. Associations between subjects' willingness ratings and affect patterns were analyzed. Additional analyses were performed to explore the role of race/ethnicity regarding these associations. Results. Clusters of affective reactions emerged that could be classified into 4 patterns: ''Moderate'' positive reactions to benefits and negative reactions to side effects (n = 186), ''Pronounced'' positive reactions to benefits and negative reactions to side effects (n = 110), feeling consistently ''Good'' (n = 58), and feeling consistently close to ''Neutral'' (n = 33). Mean (standard error) willingness to take the medication was greater among subjects feeling consistently Good 4.72 (0.20) compared with those in the Moderate 3.76 (0.11), Pronounced 3.68 (0.14), and Neutral 3.62 (0.26) groups. Black subjects with a Pronounced pattern were less willing to take the medication compared with both Hispanic (P = 0.0270) and White subjects (P = 0.0001) with a Pronounced pattern. Conclusion. Patients' affective reactions to information were clustered into specific patterns. Reactions varied by race/ethnicity and were associated with treatment willingness. Ultimately, a better understanding of how patients react to information may help providers develop improved methods of communication.
Patient reluctance to take medications that have proven benefit is widespread and an important barrier to implementing clinical practice guidelines across many different conditions. Thus, understanding the factors underlying patients' decisions are critical to improving uptake and adherence to medical therapies. Although patients' decision making is complex and influenced by a myriad of factors (e.g., patient-physician relationships, patients' beliefs and values, risk tolerance, mood, and social and contextual factors, such as insurance), numerous studies have documented the influence of affect on decision making. 1, 2 In 2002, Slovic et al. 3 proposed a theoretical framework that described the significant influence of affect on judgment and decision making. In this context, affect (integral feelings about a stimulus that are experienced as one considers a stimulus) was defined as being based in experienced feelings of goodness and badness. 4 Such emotional valence has been defined and measured with various similar terms, including positive/negative. 4 Affective reactions have a strong influence on judgments 5 and on people's tendency to neglect probabilities. For example, society is willing to pay far more to remove a chemical that might cause cancer (a dreaded risk that evokes strong negative feelings) than to develop programs to prevent cardiovascular disease (an objectively greater hazard that does not, however, evoke strong feelings of fear or dread). 6 In a recent study, Waters et al. 7 found that, of 4 components underlying side effect perceptions associated with a necessary medication (negative affect, negative impact on social or physical function, and familiarity), affect was the strongest predictor of side effect aversiveness.
There are several mechanisms by which affect may influence decision making. First, it may act as an important source of information. 1 When presented with new information, patients react with feelings toward presented facts. Those feelings rather than the facts themselves are then thought to act as information in further judgments. In particular, feeling positive about the information leads to positive judgments, whereas the opposite is true for negative feelings. 2, 3, 8 Affect can also influence decision making by refocusing attention on information consistent with the affective reaction. For example, good feelings about a medication may lead a patient to focus their attention on the medication's benefits. In addition, affect can act as a common metric by enabling patients to compare treatment options based on how they feel about them as opposed to how they appraise their specific risks and benefits. 1 Recent studies have extended our knowledge of how affect may influence decision making. In a replication and extension of earlier findings with respect to probability neglect in affect-rich scenarios, 9 Suter et al. 10 found that subjects draw upon different cognitive mechanisms when evaluating affect-rich v. affect-poor scenarios. Specifically, they found that affect-rich choices were less sensitive to probabilities and triggered activation in brain regions involved in processing emotions and memories. Affect-poor choices, on the other hand, were more sensitive to probabilities and activated brain regions known to be involved in cognitive and number processing.
Despite the influence of immediate affective responses in decision making, patients' reactions to medication information in real time have not been previously measured. Moreover, most studies have examined patients' reactions to written materials, which may not be representative of reactions to spoken words in a clinical setting. Given the importance of understanding variability in affective responses to information communicated to patients in clinical practice and its impact on decision making, the objective of this study was to examine whether patients' affective reactions to audible information influenced their willingness to take a newly described prescription medication.
In addition, because some studies have demonstrated differences in treatment preferences by race, we sought to explore whether race/ethnicity might moderate the relationship between affect and willingness. Kwoh et al.
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, for example, found that minority patients were less willing to undergo total joint replacement than their Caucasian counterparts despite having comparable or greater levels of pain and disability. Similarly, Constantinescu et al. 12 found that African American patients with active rheumatoid arthritis were less likely to choose to escalate their care compared with White patients, after adjusting for relevant sociodemographic factors. These results were due to a relative overweighting of rare complications and underweighting of benefits. 13 To capture affective reactions in real time, subjects used a dial to continuously indicate how they felt as they listened to a physician describing a new medication for pain. We examined whether: 1) affective reactions would vary; 2) subjects could be clustered by their patterns of affective reactions; and 3) specific affective reaction patterns would be associated with willingness to take medication.
Methods

Subjects
The study population was the same as described in a recent companion paper.
14 Briefly, subjects were Englishspeaking persons with a diagnosed chronic systemic 
Procedure
Subjects were randomized to listen to 1 of 5 versions of a hypothetical scenario describing a new medication. The versions varied in the amount and the order of risk benefit information. Actors were audiotaped as they read each of the 5 scripts. All versions began with the same introduction, after which the content included a brief or extended amount of information describing benefits and side effects. The 5 versions were created to examine the impact of varying risk communication strategies and have been published in a separate manuscript.
14 Because of the possible effects of the audiotaped physicians' ethnicity and gender on subjects' affective reactions and risk perceptions, [15] [16] [17] we asked each subject to select the physician from whom they would prefer to hear about a new medication by choosing 1 of 6 faces displayed on a computer screen (i.e., male or female physician of Black, White, or Hispanic race/ethnicity; images available upon request). We measured subjects' affect in real time as they listened to the description of the risks and benefits of a new medication.
Reactions were measured using the Perception Analyzer (Dialsmith), a wireless handheld response system that uses a dial and runs on a Windows platform. Data are recorded at 1-sec intervals based on the position of the dial. Ratings, mapped to the specific content of the presentation, are treated as continuous variables. Subjects were instructed to: ''Please use the dial to show your feelings about what the doctor is saying as you watch the video.'' Extreme ranges of the dial were 100= Very good on the left and 0= Very bad on the right, with the middle position 50 being neutral. 18 This conceptualization of affect is similar to that used in studies of the affect heuristic. 19 The recorded subject-generated data reflect the valence of subjects' affect. All subjects practiced using the dial while listening to a weather forecast before engaging in the study task.
After hearing the presentation, subjects rated their willingness to take the described medication on a 7-point Likert rating scale (0 = Not willing at all, 6 = Extremely willing). Self-reported data on subject demographic and clinical characteristics were also collected. Subjective numeracy (perceived numerical aptitude and preference for numbers) was measured using the 8-item Subjective Numeracy Scale. 20 A measure of numeracy was included because of previous published research documenting increased risk aversion in patients with lower levels of numeracy. [21] [22] [23] We measured subjective numeracy because of the resistance we have previously encountered in our patient population to using objective numeracy measures which ask subjects to solve mathematical problems.
Statistical Methods
The 5 scenarios coupled with the different speakers (based on the selected physician) varied in length of time and number of time points. Valid cluster analysis within each scenario, independent of the chosen speaker's presentation, required rescaling the data streams within scenarios to a common standardized timeline consisting of 100 affect response values (1 = start, 100 = end). Linear interpolation was used to rescale all signals to a standard time series of 100 equally spaced measurement times. Then, separately for each scenario, groups of similar longitudinal patterns of affect reactions were identified using a cluster-analytic statistical approach developed for classifying independent univariate time series obtained from multiple subjects. Specifically, we used a Euclidean dissimilarity approximation based on area between 2 series to generate a dissimilarity matrix between subjects' series, followed by ''partitioning-around-medoids'' (pam) for generating cluster solutions consisting of a specified number (k) of clusters. Then, for each specific k-cluster solution, ''silhouette plots'' were examined and a summary measure, ''average silhouette width'' (asw), was calculated. Visual comparison of silhouette plots and the asw indicate whether there is a good structure to the kcluster solution; i.e., whether most observations seemed to belong to the cluster to which they are assigned. This heuristic approach was used to select a ''best'' choice for the number of clusters to be retained separately for each scenario. R packages TSdist
24
, fpc 25 , and cluster 26 were used to perform the calculations and to produce the plots for each of the 5 scenarios. The emergent clusters were observed to have affect patterns that could be similarly labeled across the scenarios. For parsimony and ease of interpretability and analysis, we settled on 4 affect patterns (Moderate, Pronounced, Neutral, and Good).
We used multivariate linear regression modeling to examine the association between affect patterns and willingness to take medication. Affect was treated as a nominal 4-level categorical variable. We adjusted for variables having the potential to influence the association between affect pattern and willingness to take medication: ethnicity (3 nominal levels: Hispanic, Black, White), age, subjective numeracy, patient global assessment of disease activity, and a binary indicator of current use of a disease-modifying medication (traditional disease-modifying anti-rheumatic drug, biologic, cyclosporine, azathioprine, mycophenylate mofetil, or cyclophosphamide). 12, 13, 21, 27, 28 We adjusted P values for multiple comparisons with an adaptive linear step-up adjustment to control the false discovery rate at a = 0.05 using the SAS Ò v9.4 MULTTEST procedure. 29 Additionally, we modeled the interaction of ethnicity with affect pattern effects by including a 3-level main effect term for ethnicity, a 4-level main effect term for affect pattern, and a 3 3 4 cross-product term for modification of the affect effect by ethnicity. The adjusted estimates of the coefficients for the interactions were used to calculate the least squares means and their pairwise differences. An omnibus Type 3 sum of squares test was used to assess global statistical significance of the effect modification heterogeneity.
A single-imputation method, ''predicted means,'' was used so that 5 subjects having missing values for age could be included in the statistical analyses. Imputed values were predicted using an ordinary least-squares multiple regression algorithm to impute the most likely value. The imputation model for age consisted of the variables subjective numeracy, the use of disease-modifying drugs, ethnicity, and global score. The imputation was performed using SOLAS v4.02 (Statistical Solutions, Ltd; http://www.statsols.com/products/solas-for-missing-data/).
Results
Of the 432 subjects contacted, 395 agreed to participate in the study (91%). Of these, 2 were excluded because of hearing impairments, 1 was excluded because of a language barrier, and 5 were excluded because the computer malfunctioned.
Subject Characteristics
The mean (SD) age of the analytic sample (N = 387) was 55 (14) years. Among the group, 75% were female and 59% identified themselves as Non-Hispanic White (hereafter referred as White), 23% as Non-Hispanic Black (hereafter referred as Black), and 18% as Hispanic; participants could not choose more than one primary racial/ ethnic identity. The 3 most commonly reported systemic inflammatory diagnoses were rheumatoid arthritis (53%), systemic lupus (20%), and psoriatic arthritis (16%). Thirty-three percent reported having very good or excellent health, and most of subjects (82%) were currently taking a disease-modifying drug.
Affect Patterns
Affective reactions varied and were classified into 4 patterns. The largest group (n = 186) felt ''Moderate'' and had positive scores while listening to benefits and negative scores while listening to risks (Figure 1) . The next largest group (n = 110) also indicated feeling good and bad while listening to the benefits and risks, respectively, but had more ''Pronounced'' reactions than did the Moderate group (Figure 2) . A third group (n = 58) felt consistently ''Good'' while listening to the medication description ( Figure 3 ). These subjects' scores were more positive while listening to the benefits than to the risks, but scores remained positive throughout the scenarios. The smallest group (n = 33) exhibited little reaction and remained fairly ''Neutral'' throughout the scenarios (Figure 4 ). Two subjects were excluded from the analyses because they did not fit within 1 of the 4 affect patterns.
Subjects' clinical and demographic characteristics by affect pattern are shown in Table 1 . Of the variables measured, only ethnicity was significantly associated with affect pattern. Post hoc analyses revealed that the only significant difference was a higher than expected number of White subjects and a lower than expected number of Hispanic subjects in the Good affect pattern.
Association between Affect and Willingness to Take Medication
Mean willingness ratings by affect and ethnicity group are presented in Table 1 . After adjusting for age, subjective numeracy, current use of a disease-modifying medication, and patient global assessment of disease activity, least squares mean (standard error) willingness to take the medication was greater among subjects feeling consistently Good Given the association between affect pattern and ethnicity, we further explored the relationships between affect pattern, ethnicity, and willingness to take the medication. With few exceptions, willingness was similar across ethnic groups and affect pattern. However, estimated differences of adjusted least squares means (P values corrected for multiplicity) demonstrated that Black subjects with a Pronounced affect pattern were less willing to take the medication compared with both Hispanic (t = 2.80, P = 0.0270) and White subjects (t = 4.13, P = 0.0001) with a Pronounced pattern. In addition, both Black and White subjects who felt consistently Good were more willing to take the medication as compared with Black (t = 2.92, P = 0.0259) and White (t = 2.71, P = 0.0327) subjects with a Pronounced affect pattern. White subjects feeling consistently Good were also more willing to take the medication compared with White subjects with a Moderate affect pattern (t = 4.21, P = 0.0001). We found no association between affect pattern and willingness among Hispanic subjects. All estimated differences between ethnic groups within each affect pattern and between affect patterns within each ethnic group are included in Tables 2a and 2b . Because subjects each listened to 1 of 5 versions of the scenario, we considered version as a confounder and as an effect modifier. It did not, however, play any role in the associations between affect pattern, ethnicity, and willingness to take the medication (all significance tests . 0.05).
Discussion
Affect is known to have a significant influence on decision making across domains; people make both Figure 1 Moderate reaction to benefits and side effects (n = 186). Scenario #1: Brief benefits followed by extended side effects. Figure 2 Pronounced reaction to benefits and side effects (n = 110). Scenario #2: Extended benefits followed by extended side effects. Figure 3 Consistently Good reaction to benefits and side effects (n = 58). Scenario #3: Extended benefits followed by brief side effects. Figure 4 Consistently Neutral reaction to benefits and side effects (n = 33). Scenario #4: Extended side effects followed by brief benefits. (27) 44 (19) 17 (7) Current disease-modifying drug, n (%) 318 (82) 156 (49) 91 (29) 41 (13) 30 (9) 0.0791 b Some college, n (%) 242 (63) 118 (49) 65 (27) 42 (17) 17 (7) Figure 5 Mean* willingness to take medication per affect pattern. *LS Means adjusted for age, subjective numeracy, current use of a disease-modifying drug, and patient global disease activity. Bars indicate 95% confidence intervals. Scenario #5: Benefits followed by extended side effects followed by benefits.
important and trivial decisions based on their emotions. 1, 2, 8, 30 Despite the importance of affect, relatively few studies have quantified emotional reactions to medical information in real time, and, to the best of our knowledge, none have examined affective responses to audible information in real time.
In this study, most subjects had a Moderate affect pattern; i.e., they felt good when listening to a description of benefits and bad when listening to a description of side effects, but generally avoided the extreme ranges of the scale. The second largest group reported feeling the same pattern of affect, but with greater intensity. A small group of subjects reported more muted responses with little variability in affect; other subjects varied in the affect they reported but kept the dial in the positive range throughout the presentation. Notably, the latter reported being significantly more willing to take the medication compared with the other 3 groups. Interestingly, subjects in the consistently Good pattern reacted similarly to other groups when hearing about the benefits of the medication but did not react as negatively to the risks. Thus, it appears that willingness to take medication is driven primarily by differences in subjects' reactions to risk, as opposed to benefit, information. This finding is consistent with the study by Fried et al., 31 in which older persons' willingness to take medication for primary cardiovascular prevention was also more strongly influenced by risks than benefits. Less clear from the present data is whether affect was used as information to guide willingness to take the medication or whether negative affect towards the medication caused subjects to attend more to negative side effect-related information and less to positive information describing the benefits. 9 Consistent with previous literature demonstrating that Black subjects may be less willing to accept risky treatment or to undergo elective surgery, 11, 12, 32 Black subjects in the present study were less willing to take the medication compared with their White and Hispanic counterparts. The paired comparisons revealed that this lower willingness among Black subjects was strongest among those with a Pronounced affect pattern. These results suggest that disparities in treatment preferences may be influenced by differences in the influence of affect on judgement. The limited studies that have compared treatment preferences in Hispanic v. Non-Hispanic patients in the US demonstrate mixed results. Cooper et al. 33 found that Hispanics had weaker preferences for antidepressant medications compared with White patients. Hispanic patients are also more likely to prefer life prolonging care compared with White patients. 34 In the present study, we found no differences in willingness to take the medication in Hispanic v. Non-Hispanic subjects. Despite underutilization of treatment in rheumatoid arthritis 35 and total joint replacement 36 among Hispanic patients, few studies describing their treatment preferences in rheumatic conditions have been published. However, consistent with our findings, both Souchek et al. 37 and Byrne et al. 38 found no differences between Hispanic and White subjects' valuations for arthritis-related health states. The limitations of the study include the use of a hypothetical scenario, which enabled us to use an experimental design but cannot replicate communication between patients and their physicians. Moreover, although we adjusted for perception of disease activity and current use of medications, treatment decisions are likely also influenced by numerous other factors, such as patient-physician relationships, patients' beliefs and values, risk tolerance, mood, and other social and contextual factors, such as insurance. Whether these factors moderate affective reactions would be important to examine in future studies. One might expect, for example, that having negative attitudes towards medication might drive more Pronounced affect reactions whereas having had positive personal experiences might drive Moderate reactions.
In addition, our primary objective was to examine whether affective reactions varied among subjects and whether these affective reactions could be clustered in meaningful ways. Thus, unlike some other studies investigating the role of affect in decision making, we did not manipulate affect. As interviews were conducted in a convenient place chosen by the subject (usually their homes), objective measurements of arousal were not performed because we did not have the required equipment. We also did not include baseline measures of mood (e.g., the PANAS) in our model. Given the impact of mood on risk perceptions, 5 future research should examine whether current mood modifies affective reactions to healthrelated information. In addition, the number of subjects in specific subgroups may have limited our ability to achieve statistical significance of associations between affect and willingness to take medication among minority subjects. Moreover, we recruited a convenience sample of subjects, which limits the generalizability of our results. Lastly, although used in other fields, the software used in this study has not been validated in previous healthrelated studies.
In summary, affective reactions to information heard about a potential new medication can be clustered into distinct patterns. Subjects who did not react negatively to risk information were more willing to take a new medication compared with those who felt bad when hearing about side effects. Moreover, Black subjects with Pronounced affect patterns were less willing than Hispanic or White subjects. Ultimately, a better understanding of how patients react to information may help providers develop improved methods of communication. For example, inquiring how patients feel after hearing about side effects and further tailoring risk information to those who feel bad may prove to support decision making more effectively than trying to convince patients about the benefits of a recommended treatment. Providing these same patients with information on how best to decrease their risk or cope with side effects may also enable them to be more open to considering treatment. However, future research is needed to examine whether and how best to tailor communication based on explicit inquiry of affective reactions to risk.
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